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Letters
OBSERVATION
Secukinumab for Acrodermatitis Continua
of Hallopeau
Acrodermatitis continua of Hallopeau (ACH) was first de-
scribed in 1890byHenriHallopeau.1Hehadobserved a single
patient with an undulating but recalcitrant pustular destruc-
tionof the fingertipsandtoes.1Nowadays, thiscondition iscon-
sidered a subtype of localized pustular psoriasis.
There are no treatment guidelines available for ACH, and
the condition is refractory to many conventional topical and
systemic treatments.2 Several patients havebeen treatedwith
biologicagentswithvariable success.Targeted treatment strat-
egies based on pathogenic cytokine expression patterns have
not been evaluated for ACH.
Report of a Case | A 87-year-old retired electrical engineer had
recurrent episodes of redness, swelling, and purulent dis-
charge in the area of the left hallux with progressive degen-
eration of the toenail for 2 years. Other digits were not in-
volved.Antibiotic treatmenthadbeen ineffective.Theaffected
toe showed onychodystrophy, and the erythematous peri-
onychiumwas beset with pustules (Figure 1A). All other toes
and fingerswere normal. Findings ofmycologic and bacterial
swabswerenegative.No signs of systemic inflammationwere
present.
A medial longitudinal biopsy of the nail bed of the left
hallux revealed numerous neutrophils within the stratum
corneum, psoriasiform dermatitis with epidermal hyperpla-
sia, a lacking granular layer, and compact hyperkeratosis
and parakeratosis. These findings are compatible with the
diagnosis of acrodermatitis continua of Hallopeau (ACH).
The patient, a nonsmoker, did not have plaque-type psoria-
sis but had a family history of this condition. After ineffec-
tive treatment with topical steroids, UV-B phototherapy,
and acitretin for 9 months, the ACH flared to involve all fin-
gers (Figure 1B). The Nail Psoriasis Severity Index score
reached the maximum score of 80 points. On the pain visual
analog scale, the patient reported the maximum score, 10
of 10.
Figure 1. Clinical Findings
At presentationA Nine months after initial presentationB After treatmentC
A, Patient’s left big toe on initial presentation. B, Involvement of the fingers 9months later and shortly before initiation of treatment with secukinumab. C, Nine
weeks after treatment with secukinumab.
Figure 2. Histopathologic Findings
Normal skinA Affected skinB
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A, Normal (uninvolved) non-acral skin
sample (interleukin [IL]-17 stain,
original magnification x400).
B, Acrodermatitis continua of
Hallopeau (involved) skin sample
from the left big toe (IL-17 stain,
original magnification x400).
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In generalized pustular psoriasis (GPP), interleukin
(IL)-17 mRNA levels are elevated.3 Even though they are dis-
tinct clinical entities, ACH and GPP are closely related on
the genetic level.4 Therefore, IL-17 levels in affected skin
were evaluated in search of a therapeutic target, and strong
IL-17A expression was found (Figure 2). Therapeutic inhibi-
tion of this cytokine with the monoclonal antibody
secukinumab was evaluated in the registered dose for
plaque-type psoriasis (300 mg subcutaneously in weeks 0,
1, 2, 3, and 4 and every 4 weeks thereafter), and based on
the results of this evaluation, the patient was treated exclu-
sively with secukinumab for 6 weeks. At 6 weeks, complete
resolution of inflammation in all affected fingers was
observed, and the fingernails had begun to regrow
(Figure 1C). The patient was satisfied with the therapy,
reporting a decrease in visual analog scale pain score from
10 to 2 and an improvement of the Dermatology Life Quality
Index from 7 to 4 points. No adverse effects were reported
during the course of the therapy.
Discussion | The cytokine IL-17 plays a key role in chronic
inflammation and psoriasis pathogenesis. It acts directly on
keratinocytes and induces epidermal hyperplasia, acantho-
sis, and hyperparakeratosis and leads to recruitment and
accumulation of neutrophils, T cells, and dendritic cells.
Furthermore, IL-17 is known to enhance local neutrophil
activity under inflammatory conditions. An open-label trial
of the IL-17 inhibitor ixekizumab showed efficacy in moder-
ate to severe GPP,5 and very recently, a case report demon-
strated activity of secukinumab in GPP.6 Therefore, treat-
ment trials with inhibition of IL-17 are warranted in this
orphan disease. In addition, at least theoretically, some
degree of individualization of targeted therapies could be
achievable by detection of pathogenic cytokine expression,
such as performed here by immunohistochemical analysis
for IL-17A in affected tissue. This should be addressed in
future randomized trials.
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